Gilead Sciences, Inc. $GILD Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 49.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,444,047 shares of the biopharmaceutical company’s stock after selling 1,385,035 shares during the quarter. ProShare Advisors LLC owned about 0.12% of Gilead Sciences worth $215,235,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. PFS Partners LLC lifted its stake in Gilead Sciences by 101.1% in the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 96 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at $25,000. Laurel Wealth Advisors LLC acquired a new stake in Gilead Sciences during the third quarter worth $29,000. Kimelman & Baird LLC bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $25,000. Finally, Toth Financial Advisory Corp lifted its holdings in shares of Gilead Sciences by 85.5% during the 3rd quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on GILD shares. Scotiabank upped their target price on shares of Gilead Sciences from $177.00 to $200.00 and gave the stock a “sector outperform” rating in a research report on Friday. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. HSBC lifted their price objective on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $185.00 price target on shares of Gilead Sciences in a research report on Friday, October 23rd. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $169.19.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $170.68 on Friday. The firm has a market cap of $211.63 billion, a price-to-earnings ratio of -54.01 and a beta of 0.31. Gilead Sciences, Inc. has a 52-week low of $114.02 and a 52-week high of $175.65. The company’s 50 day moving average is $150.87 and its 200 day moving average is $139.79. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.70% and a negative net margin of 12.47%. The company had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same period last year, the business posted $2.47 EPS. The company’s revenue was up 6.8% on a year-over-year basis. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post -1.03 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is -103.80%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the transaction, the director directly owned 10,066 shares of the company’s stock, valued at $1,459,771.32. This trade represents a 33.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the transaction, the insider owned 113,684 shares of the company’s stock, valued at approximately $17,759,714.48. The trade was a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 111,000 shares of company stock worth $15,877,860 in the last three months. Insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.